Tetra Partners With Cellvera To Develop An Oral Treatment For COVID-19 Tetra Bio-Pharma Inc. Benzinga · Sep 6, 2022
Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) revealed positive preclinical results from live SARS-CoV-2 virus infection studies as well as a septic lung model, carried out by independent researchers. Benzinga · Aug 10, 2022
Tetra Bio-Pharma Opens New Subsidiary In Australia And Provides Regulatory Update Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB: TBPMF) (FRA:JAM1) launched new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd', an Australian-based research company focused on the execution of clinical trials in Australia. Benzinga · Jun 6, 2022
Tetra Bio-Pharma Receives EMA Orphan Drug Designation For A Novel Topical Therapeutic Containing CBD The European Medicines Agency (EMA) has classified Tetra Bio-Pharma Inc.’s (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) PPP004 as an orphan medicinal product for the treatment for epidermolysis bullosa (EB). Benzinga · May 18, 2022
Tetra Bio-Pharma And Cannvalate Enter Into Partnership Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) has entered into a research and development agreement with Cannvalate Pty Ltd for the initiation of the REBORN, PLENITUDE and CAUMZ clinical trials in Australia, and a subscription agreement contempl Benzinga · May 5, 2022